

April 18, 2024

То	То
The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001	The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051
Code: 540222	Code: LAURUSLABS

Dear Sirs,

Sub: <u>Q4 & FY 24 Earnings conference call invite</u>

Please find enclosed the Q4 & FY 24 Earnings conference call invite for your information and records.

Thanking you,

Yours sincerely, For Laurus Labs Limited

G. Venkateswar Reddy Company Secretary & Compliance Officer

Encl: As above

Registered Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District - 531021, Andhra Prodesh, India. CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E info@lauruslabs.com, W lauruslabs.com







Laurus Labs Ltd Q4 & Full Year FY2024 Results Conference Call to be hosted on Thursday, 25 April 2024 at 5:00pm IST

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, **on Thursday, 25 April 2024 at 5:00pm IST.** The conference call will be initiated with a brief management discussion on the Q4 & Full Year FY2024 results, followed by an interactive Question & Answer session. The call will be hosted by Antique Stock Broking.

Details of the conference call are as follows:

Date and Time	April 25, 2024 - 5:00 pm IST
Conference dial-in	
Primary Number	+91 22 6280 1342
Secondary Number	+91 22 7115 8243 Available all over India
Singapore	800101 2045
Hong Kong	800964 448
Japan	00531161110
USA	1 866 746 2133
UK	0 808 101 1573
Diamond Pass	Event Link

APRIL 18, 2024

Press Release



About Laurus | Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with an aim to improve the quality of life for millions around the world. We have a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. We also offer integrated CMO and Contract Development and Manufacturing Organization (CDMO) services to Global Innovators from Clinical phase drug development to commercial manufacturing.

We are passionate about continuous technological advances for Smart and Green chemistry skills to driven efficiencies and sustainable manufacturing backed by proven regulatory inspection and quality foundation. Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2023 Laurus generated ₹ 6,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated "BBB" by leading MSCI ESG Ratings.

Corporate Identification No: L24239AP2005PLC047518

For more information about us, please visit <u>http://www.lauruslabs.com</u> or Contact particulars:

Investor Relations

Vivek Kumar Tel: +91 40 3980 4366 Email: investorrelations@lauruslabs.com

APRIL 18, 2024

Press Release